The National Pharmaceutical Pricing Authority (NPPA) has notified revised retail prices for essential medicines, including a price fixation for Calcium and Vitamin D3 Tablets at Rs 8.93 per tablet inclusive of GST and a revision for Anti-Rabies Immunoglobulin injection to Rs 119.48. The regulator has also capped retail prices of 39 commonly used medicines for hypertension, diabetes, heart disease, and other therapies.
Price Fixation for Calcium-Vitamin D3 and Anti-Rabies Immunoglobulin
According to the official document, NPPA fixed the retail price of Calcium and Vitamin D3 Tablets at Rs 8.93 per tablet inclusive of Goods & Services Tax (GST). In a separate notification, the authority revised the rates for Anti-rabies Immunoglobulin Injection to Rs 119.48. The revision is part of NPPA's periodic review to ensure availability and affordability of critical care medicines.
Capping of 39 Medicines for Chronic Conditions
The third notification confirms that NPPA has capped the retail prices of 39 medicines, including formulations used in the treatment of hypertension, diabetes, heart disease, and other chronic conditions. The ceiling prices have been fixed under the provisions of the Drugs (Prices Control) Order, 2013. Industry officials said the inclusion of Calcium-Vitamin D3, widely prescribed for bone health and deficiency management, and Anti-Rabies Immunoglobulin, used in post-exposure prophylaxis, in the notified list will directly benefit patients and hospitals.
Impact on Affordability and Compliance
The price fixation and capping come amid the government's continued push to make essential medicines more affordable and to check excessive pricing in the market. NPPA has directed manufacturers and marketers to ensure that the revised prices are implemented immediately and that the new Maximum Retail Prices (MRP) are printed on packs along with the mandatory declaration. Retailers have been asked to ensure that stocks with old MRP are cleared as per DPCO norms. With these revisions, NPPA has now regulated prices of several key therapeutic categories in 2026, aiming to balance patient affordability with industry viability.
